The antibody response against MART-1 differs in patients with melanoma-associated leucoderma and vitiligo

Pigment Cell and Melanoma Research

Volumn 27, Issue 6, 2014, Pages 1086-1096

  Teulings, Hansje Eva ^a   Willemsen, Karin J ^a   Glykofridis, Iris ^a   Krebbers, Gabrielle ^a   Komen, Lisa ^a   Kroon, Marije W ^a   Kemp, E Helen ^b   Wolkerstorfer, Albert ^a   van der Veen, J P Wietze ^a,c   Luiten, Rosalie M ^a   Tjin, Esther P M ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c MEDICAL CENTER HAAGLANDEN   (Netherlands)

Author keywords

Antibody; Melanocyte; Melanoma; Melanoma associated leucoderma; T cell; Vitiligo

Indexed keywords

AUTOANTIBODY; GLYCOPROTEIN GP 100; MELAN A; MONOPHENOL MONOOXYGENASE;

ADULT; AGED; ANTIBODY RESPONSE; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOHISTOCHEMISTRY; INFANT; LEUKODERMA; MALE; MELANOMA; MELANOMA ASSOCIATED LEUCODERMA; MIDDLE AGED; PRESCHOOL CHILD; SCHOOL CHILD; T LYMPHOCYTE; VITILIGO; YOUNG ADULT; ADOLESCENT; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; CD8+ T LYMPHOCYTE; COMPLICATION; DEMOGRAPHY; HYPOPIGMENTATION; IMMUNOLOGY; MELANOCYTE; PATHOLOGY;

ADOLESCENT; ADULT; AGED; ANTIBODY FORMATION; ANTIBODY SPECIFICITY; CD8-POSITIVE T-LYMPHOCYTES; DEMOGRAPHY; FEMALE; HUMANS; HYPOPIGMENTATION; MALE; MART-1 ANTIGEN; MELANOCYTES; MELANOMA; MIDDLE AGED; VITILIGO; YOUNG ADULT;

EID: 84911390458     PISSN: 17551471     EISSN: 1755148X     Source Type: Journal    
DOI: 10.1111/pcmr.12294     Document Type: Article

References (33)

1. Boasberg, P.D., Hoon, D.S., Piro, L.D., Martin, M.A., Fujimoto, A., Kristedja, T.S., Bhachu, S., Ye, X., Deck, R.R., and O'Day, S.J. (2006). Enhanced survival associated with vitiligo expression during maintenance biotherapy for metastatic melanoma. J. Invest. Dermatol. 126, 2658-2663.
2. van den Boorn, J.G., Konijnenberg, D., Dellemijn, T.A., van der Veen, J.P., Bos, J.D., Melief, C.J., Vyth-Dreese, F.A., and Luiten, R.M. (2009). Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. J. Invest. Dermatol. 129, 2220-2232.
3. Cui, J., and Bystryn, J.C. (1995). Melanoma and vitiligo are associated with antibody responses to similar antigens on pigment cells. Arch. Dermatol. 131, 314-318.
4. Dordic, M., Matic, I.Z., Filipovic-Ljeskovic, I. et al. (2012). Immunity to melanin and to tyrosinase in melanoma patients, and in people with vitiligo. BMC Complement Altern. Med. 12, 109.
5. D'Souza, S., Rimoldi, D., Lienard, D., Lejeune, F., Cerottini, J.C., and Romero, P. (1998). Circulating Melan-A/Mart-1 specific cytolytic T lymphocyte precursors in HLA-A2 + melanoma patients have a memory phenotype. Int. J. Cancer 78, 699-706.
6. Ezzedine, K., Lim, H.W., Suzuki, T. et al. (2012). Revised classification/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus Conference. Pigment Cell Melanoma Res. 25, E1-E13.
7. Fishman, P., Merimski, O., Baharav, E., and Shoenfeld, Y. (1997). Autoantibodies to tyrosinase: the bridge between melanoma and vitiligo. Cancer 79, 1461-1464.
8. Garbelli, S., Mantovani, S., Palermo, B., and Giachino, C. (2005). Melanocyte-specific, cytotoxic T cell responses in vitiligo: the effective variant of melanoma immunity? Pigment Cell Res. 18, 234-242.
9. Gogas, H., Ioannovich, J., Dafni, U. et al. (2006). Prognostic significance of autoimmunity during treatment of melanoma with interferon. N. Engl. J. Med. 354, 709-718.
10. Harning, R., Cui, J., and Bystryn, J.C. (1991). Relation between the incidence and level of pigment cell antibodies and disease activity in vitiligo. J. Invest. Dermatol. 97, 1078-1080.
11. Hartmann, A., Bedenk, C., Keikavoussi, P., Becker, J.C., Hamm, H., and Brocker, E.B. (2008). Vitiligo and melanoma-associated hypopigmentation (MAH): shared and discriminative features. J. Dtsch. Dermatol. Ges. 6, 1053-1059.
12. Huang, S.K., Okamoto, T., Morton, D.L., and Hoon, D.S. (1998). Antibody responses to melanoma/melanocyte autoantigens in melanoma patients. J. Invest. Dermatol. 111, 662-667.
13. Kemp, E.H., Waterman, E.A., Hawes, B.E., O'Neill, K., Gottumukkala, R.V., Gawkrodger, D.J., Weetman, A.P., and Watson, P.F. (2002). The melanin-concentrating hormone receptor 1, a novel target of autoantibody responses in vitiligo. J. Clin. Invest. 109, 923-930.
14. Kemp, E.H., Emhemad, S., Akhtar, S., Watson, P.F., Gawkrodger, D.J., and Weetman, A.P. (2011). Autoantibodies against tyrosine hydroxylase in patients with non-segmental (generalised) vitiligo. Exp. Dermatol. 20, 35-40.
15. Koh, H.K., Sober, A.J., Nakagawa, H., Albert, D.M., Mihm, M.C., and Fitzpatrick, T.B. (1983). Malignant melanoma and vitiligo-like leukoderma: an electron microscopic study. J. Am. Acad. Dermatol. 9, 696-708.
16. Kroon, M.W., Kemp, E.H., Wind, B.S., Krebbers, G., Bos, J.D., Gawkrodger, D.J., Wolkerstorfer, A., van der Veen, J.P., and Luiten, R.M. (2013). Melanocyte antigen-specific antibodies cannot be used as markers for recent disease activity in patients with vitiligo. J. Eur. Acad. Dermatol. Venereol. 27, 1172-1175.
17. Le Gal, F.A., Avril, M.F., Bosq, J., Lefebvre, P., Deschemin, J.C., Andrieu, M., Dore, M.X., and Guillet, J.G. (2001). Direct evidence to support the role of antigen-specific CD8(+) T cells in melanoma-associated vitiligo. J. Invest. Dermatol. 117, 1464-1470.
18. Levy-Marchal, C., Bridel, M.P., Sodoyez-Goffaux, F., Koch, M., Tichet, J., Czernichow, P., and Sodoyez, J.C. (1991). Superiority of radiobinding assay over ELISA for detection of IAAs in newly diagnosed type I diabetic children. Diabetes Care 14, 61-63.
19. Merimsky, O., Shoenfeld, Y., Yecheskel, G., Chaitchik, S., Azizi, E., and Fishman, P. (1994). Vitiligo- and melanoma-associated hypopigmentation: a similar appearance but a different mechanism. Cancer Immunol. Immunother. 38, 411-416.
20. Merimsky, O., Shoenfeld, Y., Baharav, E., Zigelman, R., and Fishman, P. (1996). Reactivity to tyrosinase: expression in cancer (melanoma) and autoimmunity (vitiligo). Hum. Antibodies Hybridomas 7, 151-156.
21. Naughton, G.K., Reggiardo, D., and Bystryn, J.C. (1986). Correlation between vitiligo antibodies and extent of depigmentation in vitiligo. J. Am. Acad. Dermatol. 15, 978-981.
22. Naveh, H.P., Rao, U.N., and Butterfield, L.H. (2013). Melanoma-associated leukoderma - immunology in black and white? Pigment Cell Melanoma Res. 26, 796-804.
23. Ogg, G.S., Rod, D.P., Romero, P., Chen, J.L., and Cerundolo, V. (1998). High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo. J. Exp. Med. 188, 1203-1208.
24. Palermo, B., Garbelli, S., Mantovani, S., Scoccia, E., Da Prada, G.A., Bernabei, P., Avanzini, M.A., Brazzelli, V., Borroni, G., and Giachino, C. (2005). Qualitative difference between the cytotoxic T lymphocyte responses to melanocyte antigens in melanoma and vitiligo. Eur. J. Immunol. 35, 3153-3162.
25. Phan, G.Q., Yang, J.C., Sherry, R.M. et al. (2003). Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl Acad. Sci. USA 100, 8372-8377.
26. Pittet, M.J., Valmori, D., Dunbar, P.R., Speiser, D.E., Lienard, D., Lejeune, F., Fleischhauer, K., Cerundolo, V., Cerottini, J.C., and Romero, P. (1999). High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. J. Exp. Med. 190, 705-715.
27. Pittet, M.J., Zippelius, A., Valmori, D., Speiser, D.E., Cerottini, J., and Romero, P. (2002). Melan-A/MART-1-specific CD8 T cells: from thymus to tumor. Trends Immunol. 23, 325-328.
28. Quaglino, P., Marenco, F., Osella-Abate, S., Cappello, N., Ortoncelli, M., Salomone, B., Fierro, M.T., Savoia, P., and Bernengo, M.G. (2010). Vitiligo is an independent favourable prognostic factor in stage III and IV metastatic melanoma patients: results from a single-institution hospital-based observational cohort study. Ann. Oncol. 21, 409-414.
29. Speeckaert, R., van Geel, N., Vermaelen, K.V., Lambert, J., Van Gele, M., Speeckaert, M.M., and Brochez, L. (2011). Immune reactions in benign and malignant melanocytic lesions: lessons for immunotherapy. Pigment Cell Melanoma Res. 24, 334-344.
30. Stockert, E., Jager, E., Chen, Y.T., Scanlan, M.J., Gout, I., Karbach, J., Arand, M., Knuth, A., and Old, L.J. (1998). A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J. Exp. Med. 187, 1349-1354.
31. Teulings, H.E., Tjin, E.P., Willemsen, K.J., Krebbers, G., van Noesel, C.J., Kemp, E.H., Nieuweboer-Krobotova, L., van der Veen, J.P., and Luiten, R.M. (2013). Radiation-induced melanoma-associated leucoderma, systemic antimelanoma immunity and disease-free survival in a patient with advanced-stage melanoma: a case report and immunological analysis. Br. J. Dermatol. 168, 733-738.
32. Tjin, E.P., Konijnenberg, D., Krebbers, G. et al. (2011). T-cell immune function in tumor, skin, and peripheral blood of advanced stage melanoma patients: implications for immunotherapy. Clin. Cancer Res. 17, 5736-5747.
33. Waterman, E.A., Kemp, E.H., Gawkrodger, D.J., Watson, P.F., and Weetman, A.P. (2002). Autoantibodies in vitiligo patients are not directed to the melanocyte differentiation antigen MelanA/MART1. Clin. Exp. Immunol. 129, 527-532.